UroGen Pharma (URGN) Net Income (2017 - 2026)
UroGen Pharma (URGN) posted quarterly Net Income of -$23.6 million for Q1 2026, up 46.23% year-on-year from -$16.1 million in Q1 2025, and down 361.93% on a QoQ basis from $9.0 million in Q4 2025.
UroGen Pharma (URGN) Net Income (2017 - 2026) Analysis & Trends
UroGen Pharma (URGN) has reported Net Income for 10 consecutive years, with -$23.6 million the latest figure, recorded in Q1 2026.
- Quarterly Net Income rose 46.23% year-over-year to -$23.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$97.9 million (up 8.6% YoY) and the FY2025 annual result came in at -$118.1 million, down 23.68% from the prior year.
- Net Income eased to -$23.6 million in Q1 2026 per URGN's latest filing, from $9.0 million in the prior quarter.
- Over the last five years, Net Income for URGN reached as high as $9.0 million in Q4 2025 and fell as low as -$49.9 million in Q2 2025.
- A 5-year average of -$23.3 million and a median of -$25.8 million in 2022 frame the typical range for Net Income.
- Annual changes were most pronounced in 2024 — Net Income slumped 1284.97% — and 2025, when it jumped 246.34%.
- Year by year, Net Income stood at -$2.3 million in 2022, then soared by 122.89% to $519000.0 in 2023, then sank by 1284.97% to -$6.1 million in 2024, then soared by 246.34% to $9.0 million in 2025, then tumbled by 361.93% to -$23.6 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$23.6 million, $9.0 million, and -$33.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | UroGen Pharma | 2.13 Bn | 1.99 Bn | 46.82 Mn | -23.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.57 Mn |
| Dec 31, 2025 | 9.00 Mn |
| Sep 30, 2025 | -33.35 Mn |
| Jun 30, 2025 | -49.94 Mn |
| Mar 31, 2025 | -43.84 Mn |
| Dec 31, 2024 | -6.15 Mn |
| Sep 30, 2024 | -23.67 Mn |
| Jun 30, 2024 | -33.40 Mn |
| Mar 31, 2024 | -32.29 Mn |
| Dec 31, 2023 | 519,000.00 |
| Sep 30, 2023 | -21.88 Mn |
| Jun 30, 2023 | -24.14 Mn |
| Mar 31, 2023 | -30.21 Mn |
| Dec 31, 2022 | -2.27 Mn |
| Sep 30, 2022 | -25.83 Mn |
| Jun 30, 2022 | -26.69 Mn |
| Mar 31, 2022 | -28.39 Mn |
| Dec 31, 2021 | -1.85 Mn |
| Sep 30, 2021 | -30.21 Mn |
| Jun 30, 2021 | -26.22 Mn |